Keros Therapeutics (NASDAQ:KROS) Director Alpna Seth Sells 2,625 Shares

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Trading Down 4.4%

NASDAQ:KROS traded down $0.47 during mid-day trading on Friday, hitting $10.30. The company had a trading volume of 163,405 shares, compared to its average volume of 380,127. The business has a fifty day simple moving average of $11.35 and a 200-day simple moving average of $15.20. Keros Therapeutics, Inc. has a 1 year low of $9.79 and a 1 year high of $22.55. The firm has a market capitalization of $203.86 million, a price-to-earnings ratio of -3.42 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. As a group, research analysts anticipate that Keros Therapeutics, Inc. will post -5.23 earnings per share for the current year.

Wall Street Analyst Weigh In

KROS has been the topic of a number of analyst reports. Wells Fargo & Company dropped their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.40.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after acquiring an additional 87,129 shares during the last quarter. Western Standard LLC grew its stake in Keros Therapeutics by 42.7% in the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after purchasing an additional 654,989 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Keros Therapeutics by 26.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock worth $15,645,000 after purchasing an additional 161,336 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in Keros Therapeutics by 27.3% in the fourth quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock worth $13,330,000 after purchasing an additional 140,564 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.